Prospective Grant of Start-Up Exclusive License: Differential Expression of Molecules Associated With Acute Stroke, 59794 [2015-24988]
Download as PDF
<![CDATA[
59794
Federal Register / Vol. 80, No. 191 / Friday, October 2, 2015 / Notices
Dated: September 28, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–24983 Filed 10–1–15; 8:45 am]
BILLING CODE 4140–01–P
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
Dated: September 28, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2015–24984 Filed 10–1–15; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
National Institute of General Medical
Sciences; Notice of Closed Meetings
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Peer review of Support of Competitive
Research (SCORE) Applications.
Date: October 27, 2015.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, 3An.18,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Shinako Takada, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3An.12M, Bethesda, MD
20892, 301–594–2704, Shinako.takada@
nih.gov.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of INBRE Research Grant
Applications.
Date: October 27, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, 3An.12A,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Lee Warren Slice, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3An.12E, Bethesda, MD
20892, 301–435–0807, slicelw@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
VerDate Sep<11>2014
20:43 Oct 01, 2015
Jkt 238001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive License: Differential
Expression of Molecules Associated
With Acute Stroke
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health
(NIH), Department of Health and Human
Services, is contemplating the grant of a
start-up exclusive license to VuEssence,
which is located in Florida, to practice
the inventions embodied in the
following patents:
1. AU Patent 2005248410, issued
August 5, 2010 (E–306–2003/0–
AU–03)
2. US Patent 7,749,700, issued July 6,
2010 (E–306–2003/1–US–01)
The patent rights in these inventions
have been assigned to the United States
of America. The prospective start-up
exclusive license territory may be
worldwide and the field of use may be
limited to in vitro class III diagnostic
device for the detection and assessment
of ischemic stroke in humans.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
October 19, 2015 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated start-up exclusive
evaluation option license should be
directed to: Susan Ano, Ph.D., NINDS
Technology Transfer and Development
Branch, 31 Center Drive, Suite 8A52,
MS2540, Bethesda, MD 20892;
Telephone: (301) 435–5515; Email:
anos@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
present technology claims methods of
determining whether a subject had an
SUMMARY:
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
ischemic stroke by detecting expression
of twenty biomarkers in the blood,
comparing expression levels to an
individual who has not had a stroke,
and determining whether there was at
least a four-fold increase in the
biomarker expression levels. Each of the
biomarkers is detectable by a specified
set of sequences.
The patent also claims a method of
administering an appropriate treatment
regimen for a subject who had an
ischemic stroke.
The prospective start-up exclusive
license may be granted unless within
fifteen (15) days from the date of this
published notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the field of use filed in response to this
notice will be treated as objections to
the grant of the contemplated start-up
exclusive license. Comments and
objections submitted to this notice will
not be made available for public
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: September 28, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–24988 Filed 10–1–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
SUMMARY:
E:\FR\FM\02OCN1.SGM
02OCN1
]]>Agencies
[Federal Register Volume 80, Number 191 (Friday, October 2, 2015)]
[Notices]
[Page 59794]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-24988]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up Exclusive License: Differential
Expression of Molecules Associated With Acute Stroke
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Institutes of Health (NIH), Department of
Health and Human Services, is contemplating the grant of a start-up
exclusive license to VuEssence, which is located in Florida, to
practice the inventions embodied in the following patents:
1. AU Patent 2005248410, issued August 5, 2010 (E-306-2003/0-AU-03)
2. US Patent 7,749,700, issued July 6, 2010 (E-306-2003/1-US-01)
The patent rights in these inventions have been assigned to the
United States of America. The prospective start-up exclusive license
territory may be worldwide and the field of use may be limited to in
vitro class III diagnostic device for the detection and assessment of
ischemic stroke in humans.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
October 19, 2015 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated start-up
exclusive evaluation option license should be directed to: Susan Ano,
Ph.D., NINDS Technology Transfer and Development Branch, 31 Center
Drive, Suite 8A52, MS2540, Bethesda, MD 20892; Telephone: (301) 435-
5515; Email: anos@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The present technology claims methods of
determining whether a subject had an ischemic stroke by detecting
expression of twenty biomarkers in the blood, comparing expression
levels to an individual who has not had a stroke, and determining
whether there was at least a four-fold increase in the biomarker
expression levels. Each of the biomarkers is detectable by a specified
set of sequences.
The patent also claims a method of administering an appropriate
treatment regimen for a subject who had an ischemic stroke.
The prospective start-up exclusive license may be granted unless
within fifteen (15) days from the date of this published notice, the
NIH receives written evidence and argument that establishes that the
grant of the license would not be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the field of use filed in
response to this notice will be treated as objections to the grant of
the contemplated start-up exclusive license. Comments and objections
submitted to this notice will not be made available for public
inspection and, to the extent permitted by law, will not be released
under the Freedom of Information Act, 5 U.S.C. 552.
Dated: September 28, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-24988 Filed 10-1-15; 8:45 am]
BILLING CODE 4140-01-P
